Digitalis Ventures, a NYC-based venture capital firm, closed of its fourth fund, totaling $300m in commitments.
The new capital will be invested in entrepreneurs and researchers developing breakthrough science and technology with the potential to transform patients’ lives.
Led by Geoffrey W. Smith, Founder and Managing Partner, Digitalis Ventures has invested in over 50 companies across the US, UK, and Europe. Representative investments include Good Therapeutics, whose lead conditionally active cytokine program was acquired earlier this year by Roche; GRO Biosciences, which is scaling the production of proteins that incorporate non-standard amino acids; Terray Therapeutics, which is developing an AI-powered small molecule discovery platform; Cayaba Care, which is providing home-based pregnancy care in communities that need it most; and findhelp, the technology provider of social care infrastructure in the US.
Digitalis Ventures has built a multidisciplinary team of investors, combined with an expansive, long-term network of entrepreneurs, academic institutions, and co-investors. Companies in the portfolio benefit from team members’ accessible expertise, their deep technical understanding, and their experience in building successful businesses.
Digitalis is based in New York City, with investors in Boston, Los Angeles, San Francisco, Gainesville, and Zurich.
FinSMEs
19/10/2022